EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC
Murata H, Zhang Q, Ito T, Kawakami R, Sakamoto S, Torii S, et al
The shortcomings of existing medicines, the growing incidence of inflammatory disorders, and high financial costs associated with their treatment created the need to develop new therapeutic approaches for the treatment of these disorders
Priority Applications (6) Applications Claiming Priority (4) Related Child Applications (2) Publications (1) Family ID=62624707 Family Applications (1) Country Status (5) Cited By (2) Families Citing this family (4) Citations (2) Family Cites Families (110) 2017 2017-12-18 CN CN201780079831.4A patent/CN110121330B/en active Active 2017-12-18 EP EP17883107.9A patent/EP3558246B1/en active Active 2017-12-18 US US16/470,425 patent/US11260005B2/en active Active 2017-12-18 CA CA3046037A patent/CA3046037A1/en active Pending 2017-12-18 WO PCT/CN2017/116999 patent/WO2018113634A1/en not_active Ceased 2022 2022-01-31 US US17/589,569 patent/US11596586B2/en active Active 2023 2023-02-02 US US18/105,184 patent/US11759412B2/en active Active
Blood 64(6):12771279 Yin O, Xiong Y, Endo S, Yoshihara K, Garimella T, AbuTarif M et al (2021) Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors
Cloudiness in the reconstituted solution suggests aggregation, particularly common with hydrophobic peptides
